Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Maculopathies, Age-Related”

1,453 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,453 results

Testing effectiveness (Phase 2)Study completedNCT00006202
What this trial is testing

Lutein for Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
National Eye Institute (NEI) 45
Large-scale testing (Phase 3)Ended earlyNCT00619229
What this trial is testing

Alprostadil in Maculopathy Study (AIMS)

Who this might be right for
Macular Degeneration
UCB Pharma 37
Not applicableStudy completedNCT01350323
What this trial is testing

Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization

Who this might be right for
Age-related Macular Degeneration
University of Molise 33
Testing effectiveness (Phase 2)Study completedNCT01213082
What this trial is testing

ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)

Who this might be right for
Exudative Age-related Macular Degeneration
University of California, Davis 34
Post-approval studies (Phase 4)Study completedNCT05832996
What this trial is testing

Cool vs Room-temperature Artificial Tears

Who this might be right for
Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis)Central Retinal Vein Occlusion With Macular EdemaExudative Age-Related Macular Degeneration, Unspecified Eye+4 more
University of Iowa 124
Not applicableStudy completedNCT02464956
What this trial is testing

Production of iPSC Derived RPE Cells for Transplantation in AMD

Who this might be right for
Age Related Macular Degeneration (AMD)
Moorfields Eye Hospital NHS Foundation Trust 3
Not applicableActive Not RecruitingNCT07390253
What this trial is testing

Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular (Wet) Age-Related Macular Degeneration
Vienna Institute for Research in Ocular Surgery 50
Not applicableEnded earlyNCT04468373
What this trial is testing

Study of WA-NG (NG-IMT) Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration

Who this might be right for
Age Related Macular Degeneration
VisionCare, Inc. 9
Post-approval studies (Phase 4)Ended earlyNCT02002377
What this trial is testing

Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections

Who this might be right for
Age Related Macular Degeneration
Unity Health Toronto 23
Testing effectiveness (Phase 2)Study completedNCT05403749
What this trial is testing

Longer Interval of IVT IBI302 in Subjects With nAMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Innovent Biologics (Suzhou) Co. Ltd. 132
Large-scale testing (Phase 3)Study completedNCT02611778
What this trial is testing

Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration (AMD)
Bioeq GmbH 712
Large-scale testing (Phase 3)UnknownNCT00559715
What this trial is testing

Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab

Who this might be right for
Age-Related Neovascular Macular Degeneration
Klinikum Bremen-Mitte, gGmbH 366
Testing effectiveness (Phase 2)UnknownNCT02749734
What this trial is testing

Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases

Who this might be right for
Macular DegenerationStargardt's Macular Dystrophy
Southwest Hospital, China 15
Large-scale testing (Phase 3)Active Not RecruitingNCT06491914
What this trial is testing

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

Who this might be right for
Neovascular Age-Related Macular DegenerationDiabetic Macular Edema
Regeneron Pharmaceuticals 1,118
Not applicableStudy completedNCT01528605
What this trial is testing

Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration
Peking University 168
Not applicableUnknownNCT04469140
What this trial is testing

Non Exudative AMD Imaged With SS-OCT- Extension

Who this might be right for
Dry Macular Degeneration
Boston Image Reading Center 450
Large-scale testing (Phase 3)Study completedNCT03668054
What this trial is testing

Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)

Who this might be right for
Age-Related Macular Degeneration
Laboratorio Elea Phoenix S.A. 22
Large-scale testing (Phase 3)Study completedNCT04435366
What this trial is testing

Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Who this might be right for
Geographic AtrophyMacular Degeneration
IVERIC bio, Inc. 448
Not applicableStudy completedNCT00527553
What this trial is testing

The Effect of Eggs and Egg Products on Macular Pigment

Who this might be right for
Age-related Macular Degeneration
Maastricht University Medical Center 100
Post-approval studies (Phase 4)Study completedNCT01775124
What this trial is testing

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 332
Load More Results